BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia. The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.
KI-Analyse von BIVICTRIX THER.PLC LS-,01
Wähle eine Analyse aus und der finAgent liefert dir tiefgehende Einblicke dazu!
Neuste KI Analysen zu BIVICTRIX THER.PLC LS-,01
Für dieses Unternehmen sind noch keine KI-Threads verfügbar.